Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) EBIT Margin (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed EBIT Margin for 11 consecutive years, with 194.69% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 41313.0% to 194.69% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 326.25% through Dec 2025, down 22216.0% year-over-year, with the annual reading at 326.56% for FY2025, 22245.0% down from the prior year.
  • EBIT Margin hit 194.69% in Q4 2025 for Voyager Therapeutics, up from 228.91% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 1584.71% in Q4 2022 to a low of 3244.68% in Q1 2022.
  • Historically, EBIT Margin has averaged 605.54% across 5 years, with a median of 311.26% in 2021.
  • Biggest five-year swings in EBIT Margin: tumbled -285106bps in 2022 and later soared 332634bps in 2023.
  • Year by year, EBIT Margin stood at 20.31% in 2021, then surged by 7702bps to 1584.71% in 2022, then plummeted by -103bps to 44.24% in 2023, then tumbled by -1274bps to 607.82% in 2024, then soared by 68bps to 194.69% in 2025.
  • Business Quant data shows EBIT Margin for VYGR at 194.69% in Q4 2025, 228.91% in Q3 2025, and 704.33% in Q2 2025.